Exelixis Q3 Net Income Soars 41% on Strong Product Sales

TL;DR

**EXEL is a buy; strong cabozantinib sales and surging net income outweigh declining collaboration revenue, signaling robust core business health.**

AI Summary

EXELIXIS, INC. reported a strong financial performance for the nine months ended September 30, 2025, with total revenues increasing to $1,721,463 thousand, up from $1,601,946 thousand in the prior year period. Net product revenues significantly grew to $1,576,227 thousand from $1,294,163 thousand, driven primarily by sales of cabozantinib. However, collaboration revenues decreased substantially to $145,236 thousand from $307,783 thousand, largely due to lower license revenues. Net income saw a robust increase to $538,042 thousand, compared to $381,406 thousand in the same period of 2024, representing a 41.07% rise. Diluted net income per share also improved to $1.90 from $1.28. The company's cash and cash equivalents increased to $376,300 thousand from $217,374 thousand at December 31, 2024, despite significant common stock repurchases totaling $689,893 thousand. Research and development expenses decreased to $611,753 thousand from $661,406 thousand, while selling, general and administrative expenses rose to $395,703 thousand from $357,800 thousand. The company continues to focus on its oncology pipeline, with zanzalintinib as a lead clinical asset.

Why It Matters

Exelixis's robust net income growth and increased product revenues, primarily from cabozantinib, signal strong market acceptance and execution in the competitive oncology space. This performance could attract more investor interest, potentially driving EXEL's stock price higher, and provides capital for continued R&D, benefiting employees and future cancer patients. The decline in collaboration revenues, however, highlights a potential shift towards greater reliance on proprietary product sales, which could impact long-term revenue diversification. Competitors in the oncology market will be closely watching Exelixis's ability to sustain this growth and advance its pipeline, particularly zanzalintinib, to maintain its competitive edge.

Risk Assessment

Risk Level: medium — While net income is up significantly, the substantial decrease in collaboration revenues from $307,783 thousand to $145,236 thousand indicates a potential over-reliance on product sales, specifically cabozantinib. Additionally, the company spent $689,893 thousand on common stock repurchases, which, while boosting EPS, represents a significant cash outflow that could otherwise be used for pipeline expansion or strategic acquisitions, posing a medium-term risk if product growth slows.

Analyst Insight

Investors should consider initiating or increasing positions in EXEL, given the strong net income growth of 41.07% and robust net product revenue increase of $282,064 thousand. Monitor future collaboration revenue trends and the progress of zanzalintinib, as these will be crucial for sustained long-term growth beyond cabozantinib.

Financial Highlights

debt To Equity

0.31

revenue

$1,721,463 thousand

operating Margin

37.0%

total Assets

$2,823,547 thousand

total Debt

$662,847 thousand

net Income

$538,042 thousand

eps

$1.90

gross Margin

96.9%

cash Position

$376,300 thousand

revenue Growth

+7.5%

Revenue Breakdown

Key Numbers

• $1,721,463 thousand — Total Revenues (Increased from $1,601,946 thousand for the nine months ended September 30, 2024)
• $1,576,227 thousand — Net Product Revenues (Increased from $1,294,163 thousand for the nine months ended September 30, 2024)
• $145,236 thousand — Collaboration Revenues (Decreased from $307,783 thousand for the nine months ended September 30, 2024)
• $538,042 thousand — Net Income (Increased from $381,406 thousand for the nine months ended September 30, 2024)
• $1.90 — Diluted Net Income Per Share (Increased from $1.28 for the nine months ended September 30, 2024)
• $376,300 thousand — Cash and Cash Equivalents (Increased from $217,374 thousand at December 31, 2024)
• $689,893 thousand — Payments for Repurchases of Common Stock (Significant cash outflow for the nine months ended September 30, 2025)
• $611,753 thousand — Research and Development Expenses (Decreased from $661,406 thousand for the nine months ended September 30, 2024)
• $395,703 thousand — Selling, General and Administrative Expenses (Increased from $357,800 thousand for the nine months ended September 30, 2024)
• 268,112,157 — Shares of Common Stock Outstanding (As of October 27, 2025)

Key Players & Entities

• EXELIXIS, INC. (company) — registrant
• cabozantinib (drug) — flagship molecule and primary revenue driver
• zanzalintinib (drug) — lead clinical asset in late-stage development
• Bristol-Myers Squibb Company (company) — collaboration partner for nivolumab (OPDIVO)
• Genentech, Inc. (company) — collaboration partner for COTELLIC (cobimetinib)
• Daiichi Sankyo Company, Limited (company) — licensee for MINNEBRO (esaxerenone)
• U.S. Food and Drug Administration (FDA) (regulator) — approves pharmaceutical products
• President and Chief Executive Officer (person) — chief operating decision-maker
• The Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Securities and Exchange Commission (SEC) (regulator) — regulates financial reporting

FAQ

Risk Factors

• Competition and Market Acceptance [high — market]: The company faces intense competition from other pharmaceutical and biotechnology companies. The success of Exelixis' products, such as cabozantinib, depends on their ability to gain and maintain market acceptance and to differentiate themselves from competing therapies. Failure to do so could negatively impact revenue and profitability.
• Regulatory Approval and Compliance [high — regulatory]: Exelixis is subject to stringent regulatory oversight from agencies like the FDA. Delays or failures in obtaining regulatory approvals for new indications or products, or non-compliance with post-market surveillance requirements, can significantly hinder commercialization efforts and impact financial performance.
• Reliance on Key Products [high — financial]: The company's financial performance is heavily reliant on the sales of its key products, particularly cabozantinib. A significant decline in sales of these products due to market dynamics, competition, or regulatory issues could materially affect revenues and profitability.
• Research and Development Execution [medium — operational]: The company's future growth depends on the successful development and commercialization of its pipeline. Significant decreases in R&D spending, as seen in the nine months ended September 30, 2025 ($611,753 thousand vs $661,406 thousand), could indicate a shift in strategy or potential challenges in advancing drug candidates.
• Stock Repurchase Program [medium — financial]: Exelixis has undertaken significant common stock repurchases, totaling $689,893 thousand for the nine months ended September 30, 2025. While this can return value to shareholders, it represents a substantial cash outflow that could impact liquidity or future investment capacity if not managed prudently.
• Collaboration Revenue Volatility [medium — market]: Collaboration revenues decreased by 53.1% to $145,236 thousand for the nine months ended September 30, 2025, primarily due to lower license revenues. This highlights the inherent volatility and dependence on partnership agreements, which can fluctuate based on milestones and licensing terms.

Industry Context

The oncology pharmaceutical market is highly competitive, characterized by rapid innovation and significant R&D investment. Companies like Exelixis compete on the efficacy, safety, and market access of their therapies. Trends include the development of targeted therapies, immunotherapies, and personalized medicine, requiring continuous pipeline advancement and strategic partnerships.

Regulatory Implications

Exelixis operates under strict FDA and international regulatory frameworks. Maintaining compliance with manufacturing standards, post-market surveillance, and obtaining approvals for new indications are critical. Any regulatory setbacks or changes in the approval process could significantly impact product sales and future development.

What Investors Should Do

1. Monitor R&D pipeline progress, especially for zanzalintinib.
2. Analyze the sustainability of net product revenue growth.
3. Evaluate the impact of stock repurchases on cash reserves and future investment.
4. Assess the trend in collaboration revenues.

Key Dates

• 2025-09-30: Nine Months Ended — Reported significant revenue growth driven by net product sales and a substantial increase in net income, demonstrating strong operational performance.
• 2025-10-27: Shares of Common Stock Outstanding — As of this date, there were 268,112,157 shares outstanding, reflecting the impact of stock repurchases on share count.
• 2024-12-31: Year-End — Company had $217,374 thousand in cash and cash equivalents, which has significantly increased by September 30, 2025.

Glossary

Net Product Revenues

Revenue generated from the sale of the company's own pharmaceutical products. (Key driver of Exelixis' top-line growth, particularly from cabozantinib.)

Collaboration Revenues

Revenue earned from partnerships and licensing agreements with other companies, often including upfront payments, milestone payments, and royalties. (Indicates the company's ability to monetize its pipeline through external partnerships, though subject to volatility.)

Accumulated Deficit

The cumulative net losses of a company since its inception, offset by any net profits. (Exelixis still carries an accumulated deficit, indicating that cumulative losses have historically outweighed cumulative profits, though net income is positive for the current period.)

Right-of-use assets

Assets representing the right to use an underlying asset for a specified period, typically arising from lease agreements. (Reflects the company's long-term lease obligations for facilities and equipment.)

Marketable securities

Investments in debt or equity securities that are readily convertible into cash. (Represents a significant portion of the company's assets, providing liquidity and potential for investment returns.)

Year-Over-Year Comparison

Exelixis has demonstrated robust growth in the nine months ended September 30, 2025, with total revenues increasing by 7.5% to $1,721,463 thousand, primarily driven by a 21.8% surge in net product revenues. This strong product performance, coupled with a 41.1% increase in net income to $538,042 thousand, paints a positive financial picture. However, collaboration revenues saw a significant decline of 53.1%, indicating a shift in revenue mix. Operating expenses saw a decrease in R&D spending by 7.5% while SG&A expenses rose by 10.6%, suggesting a potential reallocation of resources. The company's cash position has strengthened considerably, despite substantial stock repurchases.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 Par Value per Share EXEL The Nasdaq Sto

Filing Documents

• exel-20251003.htm (10-Q) — 1481KB
• exel20250930exhibit31110-q.htm (EX-31.1) — 9KB
• exel20250930exhibit31210-q.htm (EX-31.2) — 9KB
• exel20250930exhibit32110-q.htm (EX-32.1) — 7KB
• exel-20251003_g1.jpg (GRAPHIC) — 54KB
• 0000939767-25-000128.txt ( ) — 7668KB
• exel-20251003.xsd (EX-101.SCH) — 51KB
• exel-20251003_cal.xml (EX-101.CAL) — 74KB
• exel-20251003_def.xml (EX-101.DEF) — 234KB
• exel-20251003_lab.xml (EX-101.LAB) — 603KB
• exel-20251003_pre.xml (EX-101.PRE) — 422KB
• exel-20251003_htm.xml (XML) — 1233KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Income (Unaudited) 4 Condensed Consolidated Statements of Comprehensive Income (Unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) 5 Condensed Consolidated Statements of Cash Flows (Unaudited) 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 25

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 40

Controls and Procedures

Item 4. Controls and Procedures 40

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 41

Risk Factors

Item 1A. Risk Factors 41

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 41

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 42

Other Information

Item 5. Other Information 42

Exhibits

Item 6. Exhibits 42

SIGNATURES

SIGNATURES 2 Tab l e o f C o n t e nts

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. EXELIXIS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share data) (unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 376,300 $ 217,374 Marketable securities 612,235 893,902 Trade receivables, net 309,725 265,437 Inventory 27,402 22,388 Prepaid expenses and other current assets 76,595 68,478 Total current assets 1,402,257 1,467,579 Non-current marketable securities 578,287 637,291 Property and equipment, net 104,748 119,391 Deferred tax assets, net 418,582 420,027 Goodwill 63,684 63,684 Right-of-use assets and other non-current assets 255,989 239,718 Total assets $ 2,823,547 $ 2,947,690 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 25,348 $ 38,191 Accrued compensation and benefits 104,364 109,830 Accrued clinical trial liabilities 57,781 57,976 Rebates and fees due to customers 58,234 62,376 Accrued collaboration liabilities 23,428 40,384 Other current liabilities 104,622 95,012 Total current liabilities 373,777 403,769 Non-current operating lease liabilities 176,463 190,823 Other non-current liabilities 112,607 108,895 Total liabilities 662,847 703,487 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.001 par value, 10,000 shares authorized and no shares issued — — Common stock, $ 0.001 par value; 400,000 shares authorized; issued and outstanding: 268,098 and 281,732 at September 30, 2025, and December 31, 2024, respectively 268 282 Additional paid-in-capital 2,262,928 2,343,915 Accumulated other comprehensive income (loss) 3,565 ( 1,347 ) Accumulated deficit ( 106,061 ) ( 98,647 ) Total stockholders' equity 2,160,700 2,244,203 Total liabilities and stockholders' equity $ 2,823,547 $ 2,947,690 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 3 Tab l e o f C o n t e nts EXELIXIS, INC. CONDENSED CONSOLI

View Full Filing

View this 10-Q filing on SEC EDGAR